title: Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
authors.forename: M
authors.initials: M
authors.lastname: Ditschkowski
authors.forename: C
authors.initials: C
authors.lastname: Haferlach
authors.forename: C
authors.initials: C
authors.lastname: Schulte
authors.forename: R
authors.initials: R
authors.lastname: Trenschel
authors.forename: D W
authors.initials: DW
authors.lastname: Beelen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016026:Bone Marrow Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology* / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate